Q-Line Biotech Secures 25% Boule Royalty Reduction Under Revised Agreement

Q-Line amended its Boule Medical licensing agreement, reducing license/royalty costs by 25% effective July 1, 2026. Revised purchase commitments, fees, advance royalties and payment terms should improve competitiveness and support instrument placements and recurring reagent volumes.